UCB has struck a deal to buy gene therapy startup Handl Therapeutics. The takeover, which was disclosed alongside a separate gene therapy collaboration, positions UCB to accelerate its push into genetic medicines. UCB stepped up its gene therapy expansion on Thursday with two deals. UCB has bought Handl for an undisclosed sum to gain control of technology platforms designed to facilitate the development of AAV gene therapy treatments for complex neurodegenerative diseases. Source: Fierce Biotech 12/11/2020